3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Thyroid Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
8
Thyroid Carcinoma, Anaplastic
5
Thyroid Cancer, Papillary
3
Endometrial Neoplasms
3
Adenocarcinoma, Follicular
3
Triple Negative Breast Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, medullary
1
Thyroid cancer, Hurthle cell
1
Thyroid Diseases
1
Thyroid Cancer Metastatic
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Locally Advanced Thyroid Gland Carcinoma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Differentiated Thyroid Cancer (DTC)
1
Interventions
pembrolizumab
13
Nivolumab
6
Docetaxel
6
cemiplimab
5
avelumab
5
atezolizumab
5
Trastuzumab
5
Carboplatin
4
durvalumab
3
Polymerase Chain Reaction
3
Magnetic Resonance Spectroscopy
3
Gene Expression Profiling
3
Gemcitabine
3
Fluorouracil
3
Cisplatin
3
Biopsy
3
zimberelimab
2
utomilumab
2
ulixertinib
2
tisotumab vedotin
2
pertuzumab
2
palbociclib
2
belinostat
2
amminedichloro(2-methylpyridine)platinum(II)
2
Tetrahydrouridine
2
Radiotherapy
2
Radiosurgery
2
Oxaliplatin
2
Nicotine
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
lenvatinib
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled